Skip to Content

Reteplase Pregnancy and Breastfeeding Warnings

Reteplase is also known as: Retavase, Retavase Half-Kit

Reteplase Pregnancy Warnings

Reteplase has been assigned to pregnancy category C by the FDA. Animal data have revealed an abortifacient effect at dosages three times the human dose (per kg basis). Other animal data at doses fifteen times the recommended human dosage (per kg basis) failed to reveal evidence of fetotoxicity, however, maternal genitourinary hemorrhage lead to abortions in mid-gestation. There are no controlled data in human pregnancy. Reteplase should only be used during pregnancy when benefit outweighs risk.

A thorough understanding of the contraindications, relative contraindications, and warnings is recommended before use of this drug or any thrombolytic agent during pregnancy. The most common complication of thrombolytic therapy is bleeding and certain conditions, including pregnancy, can increase this risk.

See references

Reteplase Breastfeeding Warnings

There are no data on the excretion of reteplase into human milk. Because many drugs are excreted in human milk, the manufacturer recommends caution when reteplase is administered to nursing women.

See references

References for pregnancy information

  1. "Product Information. Retavase (reteplase)." Boehringer Mannheim, Gaithersburg, MD.

References for breastfeeding information

  1. "Product Information. Retavase (reteplase)." Boehringer Mannheim, Gaithersburg, MD.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.